KR102678732B1 - 화합물 및 방법 - Google Patents

화합물 및 방법 Download PDF

Info

Publication number
KR102678732B1
KR102678732B1 KR1020177008280A KR20177008280A KR102678732B1 KR 102678732 B1 KR102678732 B1 KR 102678732B1 KR 1020177008280 A KR1020177008280 A KR 1020177008280A KR 20177008280 A KR20177008280 A KR 20177008280A KR 102678732 B1 KR102678732 B1 KR 102678732B1
Authority
KR
South Korea
Prior art keywords
cell
cells
subject
antigenic molecule
photosensitizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177008280A
Other languages
English (en)
Korean (ko)
Other versions
KR20170047336A (ko
Inventor
안데르스 호그셋
팔 요한센
Original Assignee
피씨아이 바이오테크 에이에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201415247A external-priority patent/GB201415247D0/en
Priority claimed from GB201420773A external-priority patent/GB201420773D0/en
Application filed by 피씨아이 바이오테크 에이에스 filed Critical 피씨아이 바이오테크 에이에스
Publication of KR20170047336A publication Critical patent/KR20170047336A/ko
Application granted granted Critical
Publication of KR102678732B1 publication Critical patent/KR102678732B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
KR1020177008280A 2014-08-28 2015-08-28 화합물 및 방법 Active KR102678732B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB201415247A GB201415247D0 (en) 2014-08-28 2014-08-28 Compound and method
GB1415247.4 2014-08-28
GB201420773A GB201420773D0 (en) 2014-11-21 2014-11-21 Compound and method
GB1420773.2 2014-11-21
PCT/EP2015/069794 WO2016030529A1 (en) 2014-08-28 2015-08-28 Compound and method

Publications (2)

Publication Number Publication Date
KR20170047336A KR20170047336A (ko) 2017-05-04
KR102678732B1 true KR102678732B1 (ko) 2024-06-25

Family

ID=54065872

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177008280A Active KR102678732B1 (ko) 2014-08-28 2015-08-28 화합물 및 방법

Country Status (9)

Country Link
US (1) US10537639B2 (enExample)
EP (1) EP3185901B1 (enExample)
JP (2) JP2017526371A (enExample)
KR (1) KR102678732B1 (enExample)
CN (1) CN108136016A (enExample)
AU (1) AU2015308345B9 (enExample)
BR (1) BR112017003486A2 (enExample)
NZ (1) NZ729408A (enExample)
WO (1) WO2016030529A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109912607B (zh) * 2018-12-11 2021-01-22 南华大学 一类卟啉-白杨素复合物及其抗肿瘤活性
WO2020170330A1 (ja) 2019-02-19 2020-08-27 大塚電子株式会社 光線力学的療法条件パラメータの決定方法および光線力学的療法装置

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520823A (ja) 2000-12-13 2004-07-15 イミュネックス・コーポレーション 不死樹状細胞系の作製方法
WO2013189663A1 (en) * 2012-05-15 2013-12-27 Pci Biotech As Conjugate of a photosensitiser and chitosan and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO180167C (no) 1994-09-08 1997-02-26 Photocure As Fotokjemisk fremgangsmåte til å innföre molekyler i cellers cytosol
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
AU2085302A (en) 2000-11-29 2002-06-11 Norwegian Radium Hospital Res Photochemical internalization for delivery of molecules into the cytosol
GB0121023D0 (en) 2001-08-30 2001-10-24 Norwegian Radium Hospital Res Compound
JP5285855B2 (ja) 2003-11-12 2013-09-11 アメリカ合衆国 膵癌を処置および予防するためのカスタムベクター
WO2005100547A1 (ja) * 2004-04-06 2005-10-27 Techno Network Shikoku Co., Ltd. 抗原パルスして得られた樹状細胞
WO2005097976A1 (ja) 2004-04-06 2005-10-20 Ehime University 抗原パルスして得られた樹状細胞
JP2011522837A (ja) 2008-06-06 2011-08-04 ベイラー リサーチ インスティテュート 呼吸器多核体ウイルスによる樹状細胞の寛容誘導
US20120269765A1 (en) 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
US20160040128A1 (en) 2013-03-15 2016-02-11 Pci Biotech As Method
EP3038619B1 (en) 2013-08-28 2023-10-04 PCI Biotech AS Compound and method for vaccination and immunisation
WO2015028575A1 (en) 2013-08-28 2015-03-05 Pci Biotech As Immunisation method by photochemical internalisation
WO2015154832A1 (en) 2014-04-11 2015-10-15 Pci Biotech As Method of treating melanoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004520823A (ja) 2000-12-13 2004-07-15 イミュネックス・コーポレーション 不死樹状細胞系の作製方法
WO2013189663A1 (en) * 2012-05-15 2013-12-27 Pci Biotech As Conjugate of a photosensitiser and chitosan and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Clinical Cancer Research. 2012. Vol.18, No.11, pp.3122-3131.*
Journal of Controlled Release. 2014. Vol.174, pp.143-150.*
Journal of Controlled Release. 2014. Vol.174, pp.413-150.*
Photodiagnosis and Photodynamic Therapy. 2007. Vol.4, pp.100-105.*

Also Published As

Publication number Publication date
JP7079819B2 (ja) 2022-06-02
AU2015308345B2 (en) 2020-12-10
JP2020182486A (ja) 2020-11-12
CN108136016A (zh) 2018-06-08
EP3185901A1 (en) 2017-07-05
CA2959207A1 (en) 2016-03-03
EP3185901C0 (en) 2023-10-04
NZ729408A (en) 2021-12-24
KR20170047336A (ko) 2017-05-04
US10537639B2 (en) 2020-01-21
WO2016030529A1 (en) 2016-03-03
AU2015308345B9 (en) 2020-12-24
BR112017003486A2 (pt) 2018-01-16
US20170252441A1 (en) 2017-09-07
JP2017526371A (ja) 2017-09-14
AU2015308345A1 (en) 2017-03-16
EP3185901B1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
EP3038619B1 (en) Compound and method for vaccination and immunisation
US9339535B2 (en) Vaccines and immunopotentiating compositions and methods for making and using them
JP6698541B2 (ja) 細胞性の細胞傷害性免疫応答を誘導または延長する方法における使用のための医薬
JP2021130713A (ja) 新規な免疫賦活法
AU2018229741A1 (en) Peptides and methods for the treatment of diabetes
Haug et al. Photochemical internalization of peptide antigens provides a novel strategy to realize therapeutic cancer vaccination
JP7079819B2 (ja) 化合物および方法
US20160040128A1 (en) Method
WO2014176604A1 (en) Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
CA2945220C (en) Method of treating melanoma
WO2015028575A1 (en) Immunisation method by photochemical internalisation
JPH07504662A (ja) 免疫無防備状態の宿主における治療用途のための免疫促進剤
WO2016030528A1 (en) Compound and method
CA2557654A1 (en) Peptides of il1 beta and tnf alpha and method of treatment using same
CA2959207C (en) Expression of an antigenic molecule on the surface of a cell using a photosensitizing agent and a cytokine
CN107970444A (zh) 复合佐剂及含有该复合佐剂的疫苗
WO2012131139A1 (es) Composiciones de vacuna para enfermedades transmitidas por birnavirus

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601